On November 16, 2026, Fulgent Genetics, Inc. (the “Company”) entered into a Lease (the “Lease”) with EP 63 Kendrick Realty LLC (the “Landlord”) for approximately 44,644 rentable square feet located at 63 Kendrick Street, Needham, Massachusetts (the “Premises”), to be used for office, research and development, diagnostic laboratory (including, without limitation, an anatomic pathology laboratory), light manufacturing and warehouse space. The term of the Lease is estimated to commence on the date that is the earlier of (i) August 1, 2027 and (ii) the date on which a final (non-temporary) Certificate of Use and Occupancy covering the Premises has been issued (the “Term Commencement Date”). The base rent will be due 180 days following the Term Commencement Date. The term of the Lease will end on the last day of the month which is 126 months after the Term Commencement Date. The initial monthly base rent is $132,071.83 per month, subject to annual increases of 3.0%. The Company has the option to extend the term of the Lease for two successive five-year periods at fair market rent.
|
Fulgent Genetics, Inc. is a technology-based company operating in clinical diagnostic genetic sequencing and therapeutic development. Founded in 2011, the company provides laboratory services including anatomic pathology, precision diagnostics, and BioPharma services. Its testing menu covers oncology, rare diseases, reproductive health, and infectious diseases, utilizing next-generation sequencing, flow cytometry, and artificial intelligence-driven digital pathology. Key products include FulGenome for whole genome sequencing, Beacon One+ for carrier screening, and the Picture telemedicine platform. The company serves insurance payors, institutional customers such as hospitals and medical institutions, and direct-to-consumer patients primarily in the United States. Fulgent Genetics also operates a therapeutic development division, Fulgent Pharma, acquired in 2022, which focuses on developing cancer drug candidates using a nanoencapsulation and targeted therapy platform. Current pipeline assets include FID-007, a nanoencapsulated paclitaxel formulation being investigated for head and neck, ampullary, and pancreatic cancers. The company utilizes proprietary gene probes, data suppression algorithms, and laboratory information management systems to support its high-throughput testing operations. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Diagnostics & Research | Homepage fulgentgenetics.com |
| Sector Healthcare | IR page ir.fulgentgenetics.com | |
|
Tags
genetic testing, anatomic pathology, next-generation sequencing, oncology, rare disease, reproductive health, digital pathology, nanoencapsulation, drug delivery, precision medicine, telemedicine, Fulgent Pharma, FulGenome, Beacon One+, Beacon Carrier Screening, Picture, Fulgent Oncology, FID-007
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 611.341M |
| Market cap (USD) | $ 611.341M |
| P/E | -6.72 |
| PEG | — |
| P/BV | 0.62 |
| P/S | 1.85 |
| P/OCF | 42.37 |
| P/FCF | -436.67 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -5.4% |
| ROI | -5.4% |
| ROIC | -6.1% |
| Profit margin | -18.8% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | 0.22% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 19 |
| Quality score | -47.1% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 322.671M | 283.47M | 289.213M | 618.968M | 992.584M | 421.712M | 32.528M | 21.351M | 18.73M | 18.276M | 9.576M |
| Net profit | -60.513M | -42.708M | -167.825M | 143.403M | 507.364M | 214.31M | -411K | -5.607M | -2.51M | -5.347M | -8.314M |
| Free cash flow | -124.212M | -19.255M | 4.796M | 234.745M | 514.765M | 105.498M | 4.335M | -2.997M | -1.564M | 617K | -3.069M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 4.36M | 4.01M | 5.95M | 6.56M | 184M | 139M | 52.7M | 51.1M | 69M | 84.8M |
| ↳ YoY growth | +106.0% | -8.2% | +48.5% | +10.2% | +2,704.8% | -24.4% | -62.0% | -3.1% | +35.0% | +22.8% |
| ↳ 5y CAGR | +144.2% | +99.8% | +67.5% | +53.8% | +60.1% | -14.3% | ||||
| Lease liabilities (USD) | — | — | 2.98M | 2.68M | 835,000 | 8.92M | 17.7M | 12.4M | 6.32M | 5.6M |
| Cash and deposits (USD) | 7.9M | 6.49M | 6.74M | 12M | 87.4M | 165M | 79.5M | 97.5M | 55.1M | 50.2M |
| Intangible assets (USD) | — | — | — | — | — | 35.9M | 151M | 143M | 135M | 133M |
| Right-of-use assets (USD) | — | — | 3M | 2.63M | 828,000 | 7.14M | 14.8M | 10.8M | 5.4M | 4.96M |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | 4.41M | 1.33M | -675,000 | 5.52M | 141M | 539M | 254M | 27M | 21.1M | -102M |
| Purchases of property, plant and equipment (USD) | -3.79M | -2.9M | -2.32M | -1.18M | -35.1M | -23.8M | -18.8M | -22.2M | -40.3M | -22.6M |
| Purchases of intangible assets (USD) | — | — | — | — | — | -32,000 | — | — | — | — |
| Change in receivables (cash effect) (USD) | -2.32M | 214,000 | -1.97M | -839,000 | -178M | 42.3M | 68.6M | 2.39M | -16.3M | -23.3M |
| Change in payables (cash effect) (USD) | 1.09M | -363,000 | 102,000 | -329,000 | 22.6M | -12.2M | -25.3M | -6.9M | 3.07M | 550,000 |
| Share buybacks (cash effect) (USD) | — | — | — | -21,000 | -62,000 | — | -74.3M | -25.1M | -225,000 | -10.9M |
| Interest paid (cash effect) (USD) | — | — | — | — | — | — | — | -960,000 | -512,000 | -52,000 |
| Income taxes paid (cash effect) (USD) | -550,000 | -757,000 | -1,000 | -20,000 | -20.6M | -237M | -56.2M | -3.26M | -27.6M | -96.4M |
| Share-based compensation (USD) | 4.65M | 2.12M | 2.3M | 3.21M | 8.16M | 15.9M | 32.6M | 42.9M | 44.5M | 39.6M |
| Operating cash flow before change in receivables (USD) | 6.73M | 1.12M | 1.3M | 6.36M | 319M | 496M | 185M | 24.6M | 37.4M | -78.4M |
| Free cash flow (OCF - PPE - intangibles) (USD) | 617,000 | -1.56M | -3M | 4.34M | 105M | 515M | 235M | 4.8M | -19.3M | -124M |
| Income detail | ||||||||||
| Research and development expense (USD) | 3.56M | 4.22M | 5.53M | 6.54M | 11.6M | 24.2M | 28.9M | 41.4M | 48.8M | 53.9M |
| ↳ 5y CAGR | +65.8% | +21.2% | +46.8% | +46.9% | +49.6% | +49.5% | +36.0% | |||
| Total comprehensive income (USD) | -5.45M | -2.45M | -5.6M | -230,000 | 215M | 505M | 119M | -152M | -45.5M | -53.8M |
| Comprehensive income to owners (USD) | -5.45M | -2.45M | -5.6M | -230,000 | 215M | 506M | 123M | -146M | -44.3M | -52.6M |
| Provision for credit losses (USD) | 76,000 | 160,000 | 309,000 | 189,000 | 1.17M | 8.93M | 32.6M | -880,000 | -1.73M | 7.65M |
| Credit cost ratio (credit losses / average receivables) (%) | 2.3% | 3.8% | 6.2% | 3.0% | 1.2% | 5.5% | 34.0% | 1.7% | 2.9% | 9.9% |
| Reported | Mar 17, 2017 | Mar 20, 2018 | May 10, 2019 | Mar 13, 2020 | Mar 8, 2021 | Feb 28, 2022 | Feb 28, 2023 | Feb 28, 2024 | Feb 28, 2025 | Feb 27, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
November 5, 2026
-
Revenue of $90.4 million, growing approximately 8% year-over-year
-
GAAP gross profit of $31.9 million, or GAAP gross margin of 35.3%; Non-GAAP gross profit of $32.8 million, or Non-GAAP gross margin of 36.3%
-
GAAP loss of $13.2 million, or $(0.48) per share; Non-GAAP loss of $2.4 million, or $(0.09) per share
-
Ended the third quarter of 2026 with $652.4 million of cash, cash equivalents, restricted cash, and investments in marketable securities
-
Maintains annual revenue guidance of $330.0-$340.0 million
-
Improves outlook for annual Non-GAAP loss and cash guidance, as a result of disciplined spend across the business
EL MONTE, Calif.--(BUSINESS WIRE)--Nov. 5, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2026.
Third Quarter 2026 Results:
-
Revenue of $90.4 million
-
GAAP loss of $13.2 million, or $(0.48) per share
-
Non-GAAP loss of $2.4 million, or $(0.09) per share
-
Adjusted EBITDA loss of $7.5 million
Non-GAAP income (loss), non-GAAP income (loss) per share, adjusted EBITDA income (loss), non-GAAP gross profit and margin, and non-GAAP operating income (loss) and margin, are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), GAAP gross profit and margin, and GAAP operating income (loss) and margin, in the accompanying tables.
Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer, said, “We are encouraged by the momentum in our therapeutics pipeline, with both FID-007 and FID-022 using our nano-drug delivery platform. In our laboratory services business, we continue to integrate AI into our workflow as utilization scales and reliability substantially increases. We expect to continue to expand our AI portfolio to drive further improvements to efficiency and quality.”
Paul Kim, Chief Financial Officer, said, “We are pleased with our third quarter results, driven by the improvement in our collection rates. We made great progress to address the billing system issue and remain confident in our outlook for the remainder of the year.”
Outlook:
For the full year 2026, Fulgent expects:
- Revenue to be in the range of $330.0-$340.0 million
For the full year 2026, Fulgent now expects:
-
Non-GAAP loss of approximately $46.0-$50.0 million
-
Non-GAAP loss of approximately $1.65-$1.75 per share, which includes the impact of a reduction of 4.1 million shares used for the stock repurchase program, year to date as of September 30, 2026
-
Cash, cash equivalents, restricted cash, and investments in marketable securities of approximately $630.0 million, which includes $64.1 million of cash used for the stock repurchase program, year to date as of September 30, 2026*
*Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company’s ongoing stock repurchase program, or other expenditures outside the ordinary course of business, including M&A. This number assumes capital purchases of $13 million, no further near-term repurchases under the stock repurchase program, and spend on the therapeutic development business of $21 million. The timing and amount of any future repurchases pursuant to the stock repurchase program will depend on a variety of factors, including the market price of Fulgent’s common stock, general market and economic conditions, and other factors Fulgent’s board of directors may deem relevant.
Conference Call Information
Fulgent will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its third quarter 2026 results. The call may be accessed through a live audio webcast in the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.
Note Regarding Non-GAAP Financial Measures
Certain information set forth in this press release and/or to be discussed on the Company’s earnings call, including non-GAAP income (loss), non-GAAP income (loss) per share, adjusted EBITDA income (loss), non-GAAP gross profit and margin, and non-GAAP operating income (loss) and margin, are non-GAAP financial measures. Fulgent believes this information is useful to investors because it provides a basis for measuring the performance of the Company’s business, excluding certain income or expense items that management believes are not directly attributable to the Company’s operating results. Fulgent defines non-GAAP income (loss) as net income (loss) calculated in accordance with accounting principles generally accepted in the United States of America, or GAAP, plus amortization of intangible assets, plus impairment loss, plus equity-based compensation expenses, plus acquisition-related costs, which include one-time banker fees, legal, valuation, due diligence, and closing costs, plus acquisition-related severance, plus or minus the non-GAAP tax effect, and plus or minus other charges or gains, as identified, that management believes are not representative of the Company’s operations. The non-GAAP tax effect was calculated by excluding from the GAAP provision the impact of the amortization of intangible assets, impairment loss, equity-based compensation expenses, acquisition-related costs, and acquisition-related severance. Fulgent defines adjusted EBITDA income (loss) as GAAP income (loss) plus or minus interest (expense) income, plus or minus provisions (benefits) for income taxes, plus depreciation and amortization, plus equity-based compensation expenses, plus insurance expense related to transferable tax credits, plus impairment loss, plus acquisition-related costs, plus acquisition-related severance, and plus or minus other charges or gains, as identified, that management believes are not representative of the Company’s operations. Fulgent defines non-GAAP gross profit as gross profit calculated in accordance with GAAP plus equity-based compensation included in cost of revenue as shown in the table below. Fulgent defines non-GAAP gross margin by taking non-GAAP gross profit and dividing it by GAAP revenue. Fulgent defines non-GAAP operating profit (loss) by taking GAAP operating profit (loss) and adding equity-based compensation expense, amortization of intangible assets, impairment of intangible assets, acquisition-related costs, and acquisition-related severance. Non-GAAP operating margin is calculated by taking non-GAAP operating profit (loss) and dividing it by GAAP revenue. Fulgent may continue to incur expenses similar to the items added to or subtracted from the GAAP financial measures, and, accordingly, the exclusion of these items in the presentation of these non-GAAP financial measures should not be construed as an implication that these items are unusual, infrequent or non-recurring. Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure in evaluating the Company’s operating performance and for internal planning and budgeting. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent may not be comparable to similarly titled metrics reported by other companies. The Company does not provide reconciliations of forward-looking non-GAAP measures to the most directly comparable GAAP measures because the information necessary to calculate such reconciliations is unavailable on a forward‑looking basis without unreasonable effort. This is due to the inherent difficulty of forecasting the timing and amounts of items that would be included in the GAAP measures, including, but not limited to, equity‑based compensation, tax effects, acquisition‑related items, and potential impairments, any of which could be material. The Company is also unable to predict the probable significance of such items.
About Fulgent
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward‑looking statements are often identified by words such as “anticipate”, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “guidance,” “intend,” “may,” “plan,” “project,” “should,” “target,” “will,” and similar expressions. Examples of forward-looking statements in this press release include statements about, among other things: future performance; guidance, including guidance regarding expected quarterly and annual financial results, revenue, GAAP loss, non-GAAP loss and related per share figures, and cash, cash equivalents, restricted cash, and investments in marketable securities; potential improvements in margins; evaluations and judgments regarding the strength of the Company’s business; the potential benefits of the continued integration of AI into the Company’s laboratory business and expansion of the Company’s AI portfolio; any references (express or implied) to the potential benefits of the StrataDx and Bako Diagnostics acquisitions, including any potential or expected revenue and whether the revenue will offset loss of other revenues; the Company’s ability to remediate operational issues relating to the transition of its billing and revenue cycle management systems; the Company’s continued and future research and development efforts, including any implications that the results of earlier clinical trials will be representative of, or consistent with later clinical trials; and the Company’s identification and evaluation of opportunities and its ability to capitalize on opportunities, capture market share, or expand its presence in certain markets; and the Company’s ability to continue to grow its business.
Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the Company’s future performance, and they are based on management’s current assumptions, expectations, and beliefs concerning future developments and their potential effect on the Company’s business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others, risks regarding: the market potential for, and the rate and degree of market adoption of, the Company’s tests; its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the Company’s ability to maintain the low internal costs of its business model; the Company’s ability to maintain an acceptable margin; risks related to volatility in the Company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the Company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the Company’s revenue; dependence on a limited number of customers, including risks that any such customer may further reduce, delay, or internalize testing volumes; risks related to the Company’s acquisitions, including Bako and StrataDx, such as integration challenges, costs, and the Company’s ability to realize expected benefits on anticipated timelines; the Company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests and testing services, including its ability to manage and to remediate billing software implementation issues and claims processing delays; the Company’s level of success in establishing and obtaining the intended benefits from partnerships, strategic investments, joint ventures, acquisitions, or other relationships; the success of the Company’s development efforts, including the Company’s ability to progress its candidates through clinical trials on the timelines expected; the outcome of the Company’s interactions with the FDA and other regulators, including whether FDA feedback on the Company’s proposed Phase 3 trial of FID-007 will require changes to the trial design that delay its commencement or increase its cost; the Company’s ability to successfully develop, validate, and deploy artificial intelligence applications in its laboratory operations, including the risk that such applications may not perform in clinical use as they have in internal testing, and evolving laws and regulations applicable to the use of artificial intelligence in diagnostic testing; the Company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; the Company’s ability to obtain expected tax refunds on the timelines expected; and the Company’s ability to protect its proprietary technology and intellectual property. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.
The forward-looking statements made in this press release speak only as of the date of this press release, and the Company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.
The Company’s reports filed with the U.S. Securities and Exchange Commission, or the SEC, including its annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 27, 2026, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, are made available on the Company’s website and on the SEC’s website at www.sec.gov upon their filing with the SEC. These reports contain more information about the Company, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release.
| FULGENT GENETICS, INC. | |
| Condensed Consolidated Balance Sheet Data | |
| September 30, 2026, and December 31, 2025 | |
| (in thousands) | | | | | | |
| | | | | | | |
| | | September 30, 2026 | | | December 31, 2025 | |
| ASSETS: | | | | | | |
| Cash and cash equivalents | | $ | 86,787 | | | $ | 50,193 | |
| Investments in marketable securities | | | 565,502 | | | | 655,153 | |
| Accounts receivable, net | | | 62,494 | | | | 84,762 | |
| Property, plant, and equipment, net | | | 110,738 | | | | 112,549 | |
| Other assets | | | 253,408 | | | | 310,868 | |
| Total assets | | $ | 1,078,929 | | | $ | 1,213,525 | |
| LIABILITIES & EQUITY: | | | | | | |
| Accounts payable, accrued liabilities and other liabilities | | $ | 94,221 | | | $ | 106,810 | |
| Total stockholders’ equity | | | 984,708 | | | | 1,106,715 | |
| Total liabilities & equity | | $ | 1,078,929 | | | $ | 1,213,525 | |
| FULGENT GENETICS, INC. | | | | | | | | | | | | |
| Condensed Consolidated Statement of Operations Data | |
| Three and Nine Months Ended September 30, 2026, and 2025 | |
| (in thousands, except per share data) | |
| (unaudited) | |
| | | | | | | | | | | | | |
| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |
| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Revenue | | $ | 90,412 | | | $ | 84,069 | | | $ | 246,939 | | | $ | 239,335 | |
| Cost of revenue (1) | | | 58,465 | | | | 48,557 | | | | 167,823 | | | | 141,042 | |
| Gross profit | | | 31,947 | | | | 35,512 | | | | 79,116 | | | | 98,293 | |
| Operating expenses | | | | | | | | | | | | |
| Research and development (1) | | | 13,636 | | | | 13,860 | | | | 42,366 | | | | 39,735 | |
| Selling and marketing (1) | | | 15,606 | | | | 11,642 | | | | 43,055 | | | | 32,393 | |
| General and administrative (1) | | | 22,761 | | | | 23,335 | | | | 77,640 | | | | 75,018 | |
| Amortization of intangible assets | | | 2,491 | | | | 2,025 | | | | 7,125 | | | | 6,005 | |
| Impairment of intangible assets | | | — | | | | — | | | | 2,172 | | | | — | |
| Total operating expenses | | | 54,494 | | | | 50,862 | | | | 172,358 | | | | 153,151 | |
| Operating loss | | | (22,547 | ) | | | (15,350 | ) | | | (93,242 | ) | | | (54,858 | ) |
| Interest income | | | 8,554 | | | | 7,874 | | | | 23,609 | | | | 23,983 | |
| Interest expense | | | (7 | ) | | | (28 | ) | | | (83 | ) | | | (59 | ) |
| Impairment of equity securities | | | — | | | | — | | | | — | | | | (9,926 | ) |
| Other (expense) income, net | | | (43 | ) | | | (5 | ) | | | 5 | | | | 109 | |
| Total other income, net | | | 8,504 | | | | 7,841 | | | | 23,531 | | | | 14,107 | |
| Loss before income taxes | | | (14,043 | ) | | | (7,509 | ) | | | (69,711 | ) | | | (40,751 | ) |
| Benefit from income taxes | | | (704 | ) | | | (683 | ) | | | (1,379 | ) | | | (2,770 | ) |
| Net loss from consolidated operations | | | (13,339 | ) | | | (6,826 | ) | | | (68,332 | ) | | | (37,981 | ) |
| Net loss attributable to noncontrolling interests | | | 187 | | | | 218 | | | | 824 | | | | 886 | |
| Net loss attributable to Fulgent | | $ | (13,152 | ) | | $ | (6,608 | ) | | $ | (67,508 | ) | | $ | (37,095 | ) |
| | | | | | | | | | | | | |
| Net loss per common share attributable to Fulgent: | | | | | | | | | | | | |
| Basic | | $ | (0.48 | ) | | $ | (0.21 | ) | | $ | (2.34 | ) | | $ | (1.21 | ) |
| Diluted | | $ | (0.48 | ) | | $ | (0.21 | ) | | $ | (2.34 | ) | | $ | (1.21 | ) |
| Weighted-average common shares: | | | | | | | | | | | | |
| Basic | | | 27,662 | | | | 30,749 | | | | 28,837 | | | | 30,708 | |
| Diluted | | | 27,662 | | | | 30,749 | | | | 28,837 | | | | 30,708 | |
| | | | | | | | | | | | | |
| (1) Equity-based compensation expense was allocated as follows: | | | | | | | | | | | | |
| Cost of revenue | | $ | 885 | | | $ | 1,697 | | | $ | 3,431 | | | $ | 5,214 | |
| Research and development | | | 2,953 | | | | 3,247 | | | | 9,626 | | | | 10,060 | |
| Selling and marketing | | | 536 | | | | 736 | | | | 1,746 | | | | 2,337 | |
| General and administrative | | | 3,746 | | | | 4,037 | | | | 11,831 | | | | 12,695 | |
| Total equity-based compensation expense | | $ | 8,120 | | | $ | 9,717 | | | $ | 26,634 | | | $ | 30,306 | |
| FULGENT GENETICS, INC. | | | | | | | | | | | | |
| Non-GAAP Income (Loss) Reconciliation | |
| Three and Nine Months Ended September 30, 2026, and 2025 | |
| (in thousands, except per share data) | |
| | | | | | | | | | | | | |
| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |
| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Net loss attributable to Fulgent | | $ | (13,152 | ) | | $ | (6,608 | ) | | $ | (67,508 | ) | | $ | (37,095 | ) |
| Amortization of intangible assets | | | 2,491 | | | | 2,025 | | | | 7,125 | | | | 6,005 | |
| Impairment loss (1) | | | — | | | | — | | | | 2,172 | | | | 9,926 | |
| Equity-based compensation expense | | | 8,120 | | | | 9,717 | | | | 26,634 | | | | 30,306 | |
| Acquisition-related costs (2) | | | — | | | | 90 | | | | 2,649 | | | | 387 | |
| Acquisition-related severance (3) | | | — | | | | — | | | | 647 | | | | — | |
| Non-GAAP tax effect | | | 134 | | | | (703 | ) | | | (1,269 | ) | | | (1,466 | ) |
| Non-GAAP (loss) income attributable to Fulgent | | $ | (2,407 | ) | | $ | 4,521 | | | $ | (29,550 | ) | | $ | 8,063 | |
| | | | | | | | | | | | | |
| Net loss per common share attributable to Fulgent: | | | | | | | | | | | | |
| Basic | | $ | (0.48 | ) | | $ | (0.21 | ) | | $ | (2.34 | ) | | $ | (1.21 | ) |
| Diluted | | $ | (0.48 | ) | | $ | (0.21 | ) | | $ | (2.34 | ) | | $ | (1.21 | ) |
| | | | | | | | | | | | | |
| Non-GAAP (loss) income per common share attributable to Fulgent: | | | | | | | | | | | | |
| Basic | | $ | (0.09 | ) | | $ | 0.15 | | | $ | (1.02 | ) | | $ | 0.26 | |
| Diluted | | $ | (0.09 | ) | | $ | 0.14 | | | $ | (1.02 | ) | | $ | 0.26 | |
| | | | | | | | | | | | | |
| Weighted average common shares: | | | | | | | | | | | | |
| Basic | | | 27,662 | | | | 30,749 | | | | 28,837 | | | | 30,708 | |
| Diluted | | | 27,662 | | | | 31,312 | | | | 28,837 | | | | 30,952 | |
| (1) Consists of non-cash charges related to (i) a 2026 impairment of an intangible asset previously acquired through a business combination and (ii) a 2025 impairment of a prior investment. |
| (2) Consists of acquisition-related costs related to the acquisitions of Bako and StrataDx for the nine months ended September 30, 2026. |
| (3) Consists of one-time severance payments to the former CEO & CFO of Bako and StrataDx for the nine months ended September 30, 2026. |
| FULGENT GENETICS, INC. | | | | | | | | | | | | |
| Non-GAAP Adjusted EBITDA Reconciliation | |
| Three and Nine Months Ended September 30, 2026, and 2025 | |
| (in thousands) | | | | | | | | | | | | |
| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |
| | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Net loss attributable to Fulgent | | $ | (13,152 | ) | | $ | (6,608 | ) | | $ | (67,508 | ) | | $ | (37,095 | ) |
| Interest income, net | | | (8,547 | ) | | | (7,846 | ) | | | (23,526 | ) | | | (23,924 | ) |
| Benefit from income taxes | | | (704 | ) | | | (683 | ) | | | (1,379 | ) | | | (2,770 | ) |
| Depreciation and amortization | | | 6,816 | | | | 6,038 | | | | 20,492 | | | | 18,011 | |
| Equity-based compensation expense | | | 8,120 | | | | 9,717 | | | | 26,634 | | | | 30,306 | |
| Insurance expense related to transferable tax credits | | | — | | | | — | | | | — | | | | 283 | |
| Impairment loss | | | — | | | | — | | | | 2,172 | | | | 9,926 | |
| Acquisition-related costs | | | — | | | | 90 | | | | 2,649 | | | | 387 | |
| Acquisition-related severance | | | — | | | | — | | | | 647 | | | | — | |
| Adjusted EBITDA | | $ | (7,467 | ) | | $ | 708 | | | $ | (39,819 | ) | | $ | (4,876 | ) |
| FULGENT GENETICS, INC. | | | | | | | | | | | | |
| Non-GAAP Operating Margin | |
| Three and Nine Months Ended September 30, 2026, and 2025 | |
| (in thousands, except percentages) | | | | | | | | | | | | |
| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |
| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |
| Revenue | | $ | 90,412 | | | $ | 84,069 | | | $ | 246,939 | | | $ | 239,335 | |
| Cost of revenue | | | 58,465 | | | | 48,557 | | | | 167,823 | | | | 141,042 | |
| Gross profit | | | 31,947 | | | | 35,512 | | | | 79,116 | | | | 98,293 | |
| Gross margin | | | 35.3 | % | | | 42.2 | % | | | 32.0 | % | | | 41.1 | % |
| | | | | | | | | | | | | |
| Equity-based compensation included in cost of revenue | | | 885 | | | | 1,697 | | | | 3,431 | | | | 5,214 | |
| Non-GAAP gross profit | | | 32,832 | | | | 37,209 | | | | 82,547 | | | | 103,507 | |
| Non-GAAP gross margin | | | 36.3 | % | | | 44.3 | % | | | 33.4 | % | | | 43.2 | % |
| | | | | | | | | | | | | |
| Operating expenses | | | 54,494 | | | | 50,862 | | | | 172,358 | | | | 153,151 | |
| Operating loss | | | (22,547 | ) | | | (15,350 | ) | | | (93,242 | ) | | | (54,858 | ) |
| Operating margin | | | -24.9 | % | | | -18.3 | % | | | -37.8 | % | | | -22.9 | % |
| | | | | | | | | | | | | | | | | |
| Equity-based compensation included in operating expenses | | | 7,235 | | | | 8,020 | | | | 23,203 | | | | 25,092 | |
| Amortization of intangible assets | | | 2,491 | | | | 2,025 | | | | 7,125 | | | | 6,005 | |
| Impairment of intangible assets | | | — | | | | — | | | | 2,172 | | | | — | |
| Acquisition-related costs | | | — | | | | 90 | | | | 2,649 | | | | 387 | |
| Acquisition-related severance | | | — | | | | — | | | | 647 | | | | — | |
| Non-GAAP operating expenses | | | 44,768 | | | | 40,727 | | | | 136,562 | | | | 121,667 | |
| Non-GAAP operating loss | | $ | (11,936 | ) | | $ | (3,518 | ) | | $ | (54,015 | ) | | $ | (18,160 | ) |
| Non-GAAP operating margin | | | -13.2 | % | | | -4.2 | % | | | -21.9 | % | | | -7.6 | % |
View source version on businesswire.com: https://www.businesswire.com/news/home/20261105293387/en/
Investor Relations Contact: The Blueshirt Group Lauren Sloane, [email protected]
Source: Fulgent Genetics, Inc.
Search Investors

Privacy Preference Center
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information
Allow All
Manage Consent Preferences
Strictly Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Targeting Cookies
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Functional Cookies
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Cookie List
Clear
- checkbox label label
Apply Cancel
Leg.Interest
checkbox label label
checkbox label label
checkbox label label
Reject Non-Essential
October 15, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Oct. 15, 2026-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.
The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.
About Fulgent
Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261015770382/en/
Investor Relations Contact: The Blueshirt Group Lauren Sloane, [email protected]
Source: Fulgent Genetics, Inc.
Search Investors

Privacy Preference Center
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information
Allow All
Manage Consent Preferences
Strictly Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Targeting Cookies
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Functional Cookies
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Cookie List
Clear
- checkbox label label
Apply Cancel
Leg.Interest
checkbox label label
checkbox label label
checkbox label label
Reject Non-Essential
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Jul 7, 2016 | Renamed | Fulgent Diagnostics, Inc. → FULGENT GENETICS, INC. |
ETFs Holding Fulgent Genetics, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| RUSC | 0.13% | 4,882 | $ 100.179K | Jun 30, 2026 |
| MKTN | 0.05% | 2,728 | $ 55.979K | Jun 30, 2026 |
| AVSC | 0.02% | 31,661 | $ 762.239K | Nov 16, 2026 |
| DFAS | 0.01% | 197,063 | $ 4.897M | Nov 12, 2026 |
| DXUV | 0.01% | 15,549 | $ 386.393K | Nov 12, 2026 |
| DFAC | 0.00% | 112,944 | $ 2.807M | Nov 12, 2026 |
| DFSU | 0.00% | 2,221 | $ 55.192K | Nov 12, 2026 |
| DCOR | 0.00% | 34,956 | $ 868.657K | Nov 12, 2026 |
| DFSV | 0.00% | 20,302 | $ 504.505K | Nov 12, 2026 |
| DFAU | 0.00% | 6,049 | $ 150.318K | Nov 12, 2026 |
| DFUS | 0.00% | 5,028 | $ 124.946K | Nov 12, 2026 |
| AVUS | 0.00% | 7,695 | $ 185.257K | Nov 16, 2026 |
| AVSU | 0.00% | 519 | $ 12.495K | Nov 16, 2026 |